L1CAM and ovarian cancer: L1CAM. Among the novel targets not previously associated with RMS before, targeting approaches are most advanced for L1CAM, which is highly and consistently overexpressed in neuroblastoma [67,68,69], ovarian cancer [70,71], and testicular germ cell tumors [72].